# US 2008/0187908 A1 · Granulocyte Subtype-Selective Receptors And Ion Channels And Uses Thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2008/0187908 A1 - Document ID: US20080187908A1 - Status: Published application - Kind: A1 - Application number: 10/591,628 - Filed: 2005-03-03 - Published: 2008-08-07 - Earliest claimed: 2004-03-03 - Inventors: Chaker N. Adra - Web page: https://patentgrep.com/patent/US20080187908A1 ## CPC - C12Q 1/6883: for diseases caused by alterations of genetic material - C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection - C12Q 2600/158: Expression markers - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES ## Abstract The invention relates, in part, to granulocyte type selective markers that are preferentially expressed in granulocytes and their use in drug screening assays. Additionally, the granulocyte type selective markers are useful in the diagnosis and treatment of granulocyte disorders and in the assessment of the efficacy of therapies of granulocyte disorders. ## Claims ### Claim 1 A method for diagnosing a granulocyte disorder comprising: detecting in a biological sample from a subject a level of expression of one or more granulocyte-selective markers, comparing the level of expression of each of the one or more granulocyte-selective markers with a reference level of expression, wherein a statistically significant difference between the level of expression of at least one granulocyte-selective marker and an expected level of expression for the at least one granulocyte-selective marker is indicative of a granulocyte disorder in the subject. ### Claim 2 (depends on 1) The method of claim 1, wherein the reference level of expression for a granulocyte-selective marker is a normal level of expression of the granulocyte-selective marker in a normal granulocyte. ### Claim 3 (depends on 1) The method of claim 1, wherein the biological sample is a blood sample. ### Claim 4 (depends on 1) The method of claim 1, wherein the biological sample is a tissue sample. ### Claim 5 (depends on 1) The method of claim 1, wherein the level of expression of each of the one or more granulocyte-selective markers is determined by determining an amount of an mRNA in the biological sample corresponding to each of the one or more granulocyte-selective markers. ### Claim 6 (depends on 5) The method of claim 5, wherein the method of determining the amount of mRNA comprises reverse transcription polymerase chain reaction (RT-PCR) amplification. ### Claim 7 (depends on 1) The method of claim 1, wherein the level of expression of each of the one or more granulocyte-selective markers is determined by determining an amount of a protein in the biological sample corresponding to each of the one or more granulocyte-selective markers. ### Claim 8 (depends on 7) The method of claim 7, wherein the method of determining the amount of a protein that corresponds to a granulocyte-selective marker comprises contacting the biological sample with an antibody that binds to the protein. ### Claim 9 (depends on 1) The method of claim 1, wherein a higher level of expression of at least one of the one or more granulocyte-selective markers in the biological sample compared to the expected level of expression for the at least one granulocyte-selective marker is indicative of the granulocyte disorder. ### Claim 10 (depends on 1) The method of claim 1, wherein a lower level of expression of at least one of the one or more granulocyte-selective markers in the biological sample compared to the expected level of expression for the at least one granulocyte-selective marker is indicative of the granulocyte disorder. ### Claim 11 (depends on 1) The method of claim 1, wherein the granulocyte disorder comprises an abnormally high number of one or more types of granulocyte in the biological sample. ### Claim 12 (depends on 1) The method of claim 1, wherein the granulocyte disorder comprises an abnormally low number of one or more types of granulocyte in the biological sample. ### Claim 13 (depends on 1) The method of claim 1, wherein the granulocyte disorder comprises an abnormal pattern of expression of one or more granulocyte selective markers in one or more types of granulocyte in the biological sample. ### Claim 14 A method for diagnosing a non-neutrophil granulocyte disorder or mast cell disorder comprising: detecting in a biological sample from a subject a level of expression of one or more non-neutrophil granulocyte or mast cell selective markers, comparing the level of expression of each of the one or more non-neutrophil granulocyte or mast cell selective markers with a reference level of expression, wherein a statistically significant difference between the level of expression of at least one non-neutrophil granulocyte or mast cell selective marker and an expected level of expression for the at least one non-neutrophil granulocyte or mast cell selective marker is indicative of a non-neutrophil granulocyte disorder or mast cell disorder in the subject. ### Claim 15 (depends on 14) The method of claim 14, wherein the non-neutrophil granulocyte disorder is a basophil disorder. ### Claim 16 (depends on 15) The method of claim 15, wherein the basophil disorder is a basophil-associated tumor or cancer. ### Claim 17 (depends on 14) The method of claim 14, wherein the non-neutrophil granulocyte disorder is an eosinophil disorder. ### Claim 18 (depends on 17) The method of claim 17, wherein the eosinophil disorder is an eosinophil-associated tumor or cancer. ### Claim 19 (depends on 14) The method of claim 14, wherein the mast cell disorder is a mast cell-associated tumor or cancer. ### Claim at position 20 20-48. (canceled) ### Claim 49 An assay for identifying a compound that alters at least one physiological property of a granulocyte comprising: contacting a granulocyte with a candidate compound that interacts with a granulocyte-selective marker, determining at least one physiological property of the granulocyte after contact with the candidate compound, comparing the at least one physiological property to one at least one reference property to determine whether the candidate compound alters at least one physiological property of the granulocyte. ### Claim at position 22 50-71. (canceled)